Serosurveillance of Post vaccination SARS-CoV-2 antibodies in Covishield and Covaxin Vaccinated Subjects.

Background: Whole virion (attenuated) vaccine (Covaxin) and m-RNA of whole Spike protein (Covishield) were used as emergency measures in SARS-CoV-2 infection. Aim & Objective: To evaluate the antigenicity of both vaccines by measuring the quantum of antibodies. Methods and Material: Periodic antigen...

Descripción completa

Detalles Bibliográficos
Publicado en:Indian Journal of Community Health Vol. 36; no. 5; pp. 661 - 674
Autores principales: Barthwal, Shilpa, Angel, Bennet, Angel, Annette, Joshi, Vinod, Praveen, Uppu, Khaneja, Poorna, Buvvaji, Shareef Mohammed, Joshi, Ramesh
Formato: research tables/charts Journal Article
Publicado: Indian Journal of Community Health Oct2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=181466906&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 181466906
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09717587
        DURZ
      jtl: Indian Journal of Community Health
      issn: 09717587
      maglogo: N
    pubinfo:
      dt: Oct2024
      vid: 36
      iid: 5
      pid: 24450
      pub: Indian Journal of Community Health
    artinfo:
      ui:
        181466906
        181466906
        181466906
        10.47203/IJCH.2024.v36i05.007
        181466906
      ppf: 661
      ppct: 13
      formats:
      tig:
        atl: Serosurveillance of Post vaccination SARS-CoV-2 antibodies in Covishield and Covaxin Vaccinated Subjects.
      aug:
        au:
          Barthwal, Shilpa
          Angel, Bennet
          Angel, Annette
          Joshi, Vinod
          Praveen, Uppu
          Khaneja, Poorna
          Buvvaji, Shareef Mohammed
          Joshi, Ramesh
        affil: Centre of Excellence in Virology & Immunology, Sharda University, Greater Noida, Uttar Pradesh
      sug:
        subj:
          COVID-19 Prevention and Control
          COVID-19 Vaccines Therapeutic Use
          Immunization
          Antigens Blood
          COVID-19 Vaccines Immunology
          Antibodies, Viral Blood
          Vaccine Efficacy
          Human
          Male
          Female
          Adolescence
          Adult
          Middle Age
          Aged
          Immunoglobulins
          India
          Data Analysis Software
          Inferential Statistics
          Chi Square Test
          Fisher's Exact Test
          Descriptive Statistics
          Funding Source
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Background: Whole virion (attenuated) vaccine (Covaxin) and m-RNA of whole Spike protein (Covishield) were used as emergency measures in SARS-CoV-2 infection. Aim & Objective: To evaluate the antigenicity of both vaccines by measuring the quantum of antibodies. Methods and Material: Periodic antigenicity of both the vaccines post-vaccination i.e. after 5-6 and 11-12 months was undertaken in two categories; those who were not infected and vaccinated and secondly infected and vaccinated and got re-infected (after vaccination). Results: Both the categories of patients showed similar quantum of IgA/IgG/ IgM and Neutralizing antibodies generated by Covaxin. In subjects, vaccinated by Covishield, the recipients of single dose of vaccine showed higher titre of antibodies than double dose vaccinated. Less antigenicity of Covishield vaccine in infected vaccinated was seen compared to un-infected vaccinated subjects. Conclusions: Paper reports antigenic strength of both the vaccines during 5-6 and 11-12 months' post-vaccination and also the important point that antibodies titre was higher among cohort of single vaccinated as compared to those who received two doses of vaccines. The paper further sensitises the issue that both the vaccines were developed on the Wuhan strain whereas the virus has mutated twice, generating two new subsequent strains namely Delta and Omicron.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N